These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://lawsonmceb317729.tinyblogging.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-83104114